Are there concerns with combining anti-IL5 biologics (mepolizumab or benralizumab) for severe asthma with other biologics for RA?  

The question of combination biologic therapy is becoming increasingly important in our field. The main concern with combination biologic therapy is the risk of serious infections. This concern extends to IL-5 agents combined with biologics for RA. Unfortunately, there is a lack of data to guide our ...